303 related articles for article (PubMed ID: 16597201)
1. Treatment options for visceral leishmaniasis.
den Boer M; Davidson RN
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):187-97. PubMed ID: 16597201
[TBL] [Abstract][Full Text] [Related]
2. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M
Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough in the management of visceral leishmaniasis.
Thakur BB
J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
[No Abstract] [Full Text] [Related]
4. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
5. Engima of therapeutic failure in visceral leishmaniasis.
Arya SC
J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
[No Abstract] [Full Text] [Related]
6. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
7. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
8. Visceral leishmaniasis in children: a review.
Palumbo E
Minerva Pediatr; 2010 Aug; 62(4):389-95. PubMed ID: 20940672
[TBL] [Abstract][Full Text] [Related]
9. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
10. Developments in the treatment of visceral leishmaniasis.
den Boer ML; Alvar J; Davidson RN; Ritmeijer K; Balasegaram M
Expert Opin Emerg Drugs; 2009 Sep; 14(3):395-410. PubMed ID: 19708817
[TBL] [Abstract][Full Text] [Related]
11. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
12. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani.
Kothari H; Kumar P; Sundar S; Singh N
Parasitol Int; 2007 Mar; 56(1):77-80. PubMed ID: 17169604
[TBL] [Abstract][Full Text] [Related]
13. Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.
Thornton SJ; Wasan KM; Piecuch A; Lynd LL; Wasan EK
Drug Dev Ind Pharm; 2010 Nov; 36(11):1312-9. PubMed ID: 20545513
[TBL] [Abstract][Full Text] [Related]
14. Drug combinations for visceral leishmaniasis.
Olliaro PL
Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovanib - knocking the door.
Kamath S; Avi H; Mehta PJ
J Assoc Physicians India; 1995 May; 43(5):315-6. PubMed ID: 9081956
[No Abstract] [Full Text] [Related]
16. Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.
Verma SK; Ahmad S; Shirazi N; Kusum A; Kaushik RM; Barthwal SP
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):730-2. PubMed ID: 17382981
[TBL] [Abstract][Full Text] [Related]
17. Visceral leishmaniasis: can we dream its eradication?
Rege NN
J Assoc Physicians India; 2001 Jun; 49():605-8. PubMed ID: 11584933
[No Abstract] [Full Text] [Related]
18. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Shakya N; Sane SA; Vishwakarma P; Gupta S
Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
[TBL] [Abstract][Full Text] [Related]
19. [Leishmaniasis: progress in diagnosis, treatment and prevention].
Veeken H; Ritmeijer K
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2686-8. PubMed ID: 17194002
[TBL] [Abstract][Full Text] [Related]
20. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
